The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma

NAZLI GÜLSOY KIRNAP
ÖZLEM TURHAN İYİDİR
YUSUF BOZKUŞ
ŞERİFE MEHLİKA İŞİLDAK
CÜNEYD ANIL

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
KIRNAP, NAZLI GÜLSOY; İYİDİR, ÖZLEM TURHAN; BOZKUŞ, YUSUF; İŞİLDAK, ŞERİFE MEHLİKA; ANIL, CÜNEYD; FIRAT, SEVDE NUR; DEMİR, CANAN; NAR, ASLI; and TÜTÜNCÜ, NESLİHAN BAŞÇIL (2020) "The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma," Turkish Journal of Medical Sciences: Vol. 50: No. 4, Article 30. https://doi.org/10.3906/sag-1902-176
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss4/30

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma

Authors
NAZLI GÜLSOY KIRNAP, ÖZLEM TURHAN İYİDİR, YUSUF BOZKUŞ, ŞERİFE MEHLİKA IŞILDAK, CÜNEYD ANIL, SEVDE NUR FIRAT, CANAN DEMİR, ASLI NAR, and NESLİHAN BAŞÇIL TÜTÜNCÜ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol50/iss4/30
The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma

Nazlı GÜLSOY KIRNAP*, Özlem TURHAN İYİDİR, Yusuf BOZKUŞ, Şerife Mehlika İŞILDAK, Cüneyd ANIL, Sevde Nur FIRAT, Canan DEMİR, Ash NAR, Neslihan BAŞÇIL TÜTÜNCÜ

Department of Endocrinology and Metabolism, Faculty of Medicine, Başkent University, Ankara, Turkey

* Correspondence: kirnapnazli@hotmail.com

1. Introduction

Differentiated thyroid carcinoma is the most common type of endocrinological neoplasm [1]. The disease has a general mortality rate of less than 10%, and most patients have a long survival due to the tumour’s biological behaviour and treatment’s efficacy [2]. Conventional treatment for DTC includes total or partial thyroidectomy, remnant tissue radioactive iodine (RAI) ablation, and thyroid stimulating hormone/thyrotropin (TSH) suppression with LT4. The latter serves to create an exogenous SCH (a normal serum free T3 (fT3) free T4 (fT4) but with a reduced TSH concentration) [3]. These chemical changes are associated with increased cardiovascular risk, fatigue, reduced bone mineral density, and impaired muscle function [4–7]. Such changes may affect patients’ physical and psychological status and impair their quality of life (QoL) [7,8] and they may also be associated with depression [9,10] and anxiety [11,12]. Affect and anxiety disorders are more common among patients with thyroid disorders [13]. Patients with DTC may suffer SCH symptoms, which may impair QoL [14,15]. The aim of the present study is to investigate the effects of exogenous SCH during the follow-up of differentiated thyroid cancers on patients’ QoL and symptoms of anxiety-depression.

2. Materials and methods

2.1. Study population

A total of 278 patients who underwent thyroid surgery and admitted to Başkent University Ankara Hospital, Endocrinology outpatient clinic between 01/2015–01/2016 were included in the study. The patients were divided into exogenous SCH by LT4-DTC (n = 127), euthyroid-DTC (n = 66) and exogenous euthyroid-benign thyroid nodule (BTN) who underwent thyroidectomy for benign thyroid pathology (n = 85) groups.

Results: The rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group (27.5%, n = 35 vs. 9.4%, n = 8) (P = 0.001). TSH levels and Beck anxiety inventory (BAI) scores were significantly negatively correlated (P = 0.009 r = –0.16). Free T4 and BAI were significantly positively correlated (P = 0.04 r = 0.4). The groups were similar in terms of depression severity (P = 0.15). Subclinical hyperthyroid-DTC group scored significantly lower than euthyroid-BTN group in all scales of SF-36 quality of life survey.

Conclusion: LT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and disrupt their quality of life, depending on the level of fT4.

Keywords: Beck anxiety and depression inventory, differentiated thyroid carcinoma, SF-36 quality of life survey, subclinical hyperthyroidism, TSH suppression

Received: 21.02.2019 • Accepted/Published Online: 19.05.2020 • Final Version: 23.06.2020

This work is licensed under a Creative Commons Attribution 4.0 International License.
their own, with no previous history of psychiatric disorder or substance abuse were included in the study. Free T3, fT4 and TSH levels were measured and recorded from the patients’ fasting blood samples, before the administration of LT4. Serum TSH (0.48–4.94 mU/L), fT4 (0.7–1.48 ng/dL), fT3 (1.71–3.71 ng/L) levels were measured using electro-chemiluminescence immunoassay (ECLIJA) method. Subclinical hyperthyroidism was defined as having serum TSH levels below the reference range, and fT3 and fT4 levels within the reference range [2].

2.2. Instruments

2.2.1. Beck depression inventory (BDI)/Beck anxiety inventory (BAI)

This inventory is a self-assessment scale for rating a patient's level and severity of depression/anxiety. It aims to rate the severity of depressive symptoms. It consists of 21 items, each of which is scored between 0–3 points. A high total point indicates a more severe depression/anxiety. A score of 0–13 is considered normal; 14–19 points indicate mild depression; 20–28 points indicate moderate depression, and 29–63 points indicate severe depression [16]. As for BAI; 0–7 points are considered normal; 8–15 points indicate mild anxiety; 16–25 points indicate moderate anxiety; and 26–63 points indicate severe anxiety [17]. The reliability and validity of the Turkish versions of these instruments have been examined [18,19].

2.2.2. Health survey short form-36 (SF-36)

The SF-36 is used to assess QoL [20]. This instrument is a 36-item self-report questionnaire with eight scales measuring major domains of functional health and well-being, role limitations due to physical problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems and mental health. Each scale provides a score ranging from 0 to 100, with higher scores indicating better health status. The validity and reliability of the Turkish versions of SF-36 have been extensively documented [21].

2.3. Data analysis

For this study’s power analysis, G-power 3.1 softwares were used. In the study, 3 independent groups were compared. Power test F test ANOVA one-way was used. In the study, effect size 0.24 Type 1 error was taken 0.05 and the power of the study is 95%. All data analyses were performed with SPSS software (Statistical Package for the Social Sciences, version 15.0). Normality distribution analysis of the data was performed by using Kolmogorov-Smirnov and Shapiro-Wilk tests. One-way ANOVA analysis of variance and Tukey’s multiple comparison posthoc tests were used for comparison of qualitative variables among groups. The differences between independent groups in terms of numerical variables were examined using the Student's t-test to compare means. Chi-square ($\chi^2$) test was used to analyze categorical variables. Pearson’s tests were used to test correlations and the degree of associations among variables. A P-value of < 0.05 was considered statistically significant.

3. Results

The groups were similar in terms of the mean age and sex distribution of patients (P = 0.68 P = 0.3). Free T4 level was significantly higher in SCH-DTC group than euthyroid-BTN group (P = 0.002), and was similar to the level in euthyroid-DTC group (P = 0.17) (Table 1).

When groups were compared in terms of BDI, it was found that 72.4% (n = 92) of the patients in SCH-DTC group were normal, whereas 16.5% (n = 21) had mild, 8.7% (n = 11) had moderate, and 2.4% (n = 3) had severe depression. In euthyroid-DTC group, 83.3% (n = 55) of the patients were normal, whereas 9.1% (n = 6) had mild, 6.1% (n = 4) had moderate, and 1.5% (n = 1) had severe depression. In euthyroid-BTN group, 87.1% (n = 74) of the patients were normal, and 10.6% (n = 9) had mild, 1.2% (n = 1) had moderate, and 1.2% (n = 1) had severe depression, and the groups were similar in terms of rates of depression severity (P = 0.15) (Table 2). When groups were compared in terms of BAI, it was found that 32.3% (n = 41) of the patients in SCH-DTC were normal, whereas 40.2% (n = 51) had mild, 15.7% (n = 20) had moderate, and 11.8% (n = 15) had severe anxiety. In euthyroid-DTC group, 57.6% (n = 38) of the patients were normal, and 24.2% (n = 16) had mild, 13.6% (n = 9) had moderate and 4.5% (n = 3) had severe anxiety. In euthyroid-BTN group, 48.2% (n = 41) of the patients were normal, and 42.4% (n = 36) had mild, 9.4% (n = 8) had moderate anxiety and severe anxiety was not detected in any of the patients. The rate of moderate/severe anxiety in SCH-DTC group was 27.5% (n = 35), which was significantly higher than euthyroid-BTN group with 9.4% (n = 8) (P = 0.001) (Table 2).

In terms of SF-36 quality of life survey, SCH-DTC group scored lower than euthyroid-BTN group in all scales of the survey (physical functioning, role limitation due to physical problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health) (P < 0.001, P = 0.03, P < 0.002, P < 0.001, P < 0.001, P < 0.001, P < 0.001). Vitality and mental health scores were significantly lower in SCH-DTC group than euthyroid-DTC group (P = 0.007, P = 0.03, respectively) (Table 3).

In the correlation analysis, no significant correlation was detected between TSH levels and BDI scores (P = 0.073 r = –0.1). A significant negative correlation was detected between TSH levels and BAI scores (P = 0.009 r =
In terms of SF-36 quality of life survey, a statistically significant weak positive correlation was detected between TSH and physical functioning, body pain, general health, vitality, social functioning and mental health scales \((r = 0.16\) \(P = 0.015\), \(r = 0.14\) \(P = 0.006\), \(r = 0.16\) \(P = 0.002\), \(r = 0.18\) \(P = 0.001\), \(r = 0.15\) \(P = 0.001\), \(r = 0.2\) \(P = 0.001\), respectively). No correlation was detected between role limitation due to physical and emotional problems scales and TSH \((r = 0.2\) \(P = 0.07\), \(r = 0.1\) \(P = 0.1\), respectively). A significant negative correlation was detected between fT4 and vitality, social functioning and mental health scales of SF-36 quality of life survey \((r = -0.42\) \(P = 0.04\), \(r = -0.4\) \(P = 0.01\), \(r = -0.48\)). A significant positive correlation was detected between fT4 and BAI \((r = 0.04\) \(P = 0.4\). There was no significant correlation between fT3 and SF36, BDI and BAI socres (Table 4).

Table 1. General characteristics of the study groups.

| Characteristics | SCH-DTC n = 127 | Euthyroid-DTC n = 66 | Euthyroid-BTN n = 85 | P   | p*   | p**  | p*** | p*** |
|-----------------|-----------------|----------------------|----------------------|-----|------|------|------|------|
| Age ± SD        | 51.92 ± 11.82   | 51.62 ± 14.06        | 50.1 ± 12.17         | 0.68|      |      |      |      |
| Sex             |                 | 0.3                  |                       |     |      |      |      |      |
| Female n (%)    | 106 (83.5)      | 53 (80.3)            | 61 (71.8)            |     |      |      |      |      |
| Male n (%)      | 21 (16.5)       | 13 (19.7)            | 24 (28.2)            |     |      |      |      |      |
| TSH mU/L ± SD   | 0.12 ± 0.12     | 1.14 ± 0.73          | 1.9 ± 1.27           | <0.001| <0.001| <0.001|     |      |
| fT3 ng/L ± SD   | 3.1 ± 0.26      | 2.8 ± 0.35           | 2.87 ± 0.35          | 0.051| 0.13 | 0.66 |      |      |
| fT4 ng/dL ± SD  | 1.33 ± 0.22     | 1.24 ± 0.14          | 1.12 ± 0.13          | 0.17 | 0.002| 0.06 |      |      |

DTC: Differentiated thyroid cancer, BTN: Benign thyroid nodule, fT3: Free triiodothyronine, fT4: Free thyroxine, SCH: Subclinical hyperthyroidism, TSH: Thyroid stimulating hormone, SD: Standard deviation, P: Difference between all groups, P*: Difference between SCH-DTC and euthyroid-DTC, P**: Difference between SCH-DTC and euthyroid-BTN, P***: Difference between euthyroid-DTC and euthyroid-BTN, P-value <0.05 was considered statistically significant, Age P: Difference between SCH-DTC, euthyroid-DTC and euthyroid-BTN (ANOVA test), Sex P: Difference between SCH-DTC, euthyroid-DTC and euthyroid-BTN (Chi-square test), p* p** p***: Student’s t- test.

Table 2. Comparison of groups in terms of Beck depression and anxiety scores.

| Beck depression score | SCH-DTC n = 127 | Euthyroid-DTC n = 66 | Euthyroid-BTN n = 85 | p   | p*   | p**  | p*** | p*** |
|----------------------|-----------------|----------------------|----------------------|-----|------|------|------|------|
| Normal (0–13) n (%)  | 92 (72.4)       | 55 (83.3)            | 74 (87.1)            | 0.15|      |      |      |      |
| Mild (14–19) n (%)   | 21 (16.5)       | 6 (9.1)              | 9 (10.6)             |     |      |      |      |      |
| Moderate (20–28) n (%)| 11 (8.7)       | 4 (6.1)              | 1 (1.2)              |     |      |      |      |      |
| Severe (29–63) n (%) | 3 (2.4)         | 1 (1.5)              | 1 (1.2)              |     |      |      |      |      |

Beck anxiety score

| Beck anxiety score | SCH-DTC n = 127 | Euthyroid-DTC n = 66 | Euthyroid-BTN n = 85 | p   | p*   | p**  | p*** | p*** |
|-------------------|-----------------|----------------------|----------------------|-----|------|------|------|------|
| Normal (0–7) n (%) | 41 (32.3)       | 38 (57.6)            | 41 (48.2)            | 0.001| 0.001| 0.01 | 0.25 |      |
| Mild (8–15) n (%)  | 51 (40.2)       | 16 (24.2)            | 36 (42.4)            | 0.03 | 0.028| 0.75 | 0.02 |      |
| Moderate (16–25) n (%) | 20 (15.7)       | 9 (13.6)             | 8 (9.4)              | 0.41|      |      |      |      |
| Severe (26–63) n (%)| 15 (11.8)       | 3 (4.5)              | 0 (0)                | 0.002| 0.1  | 0.001| 0.08 |      |
| Moderate + Severe n (%) | 35 (27.5)      | 12 (18.1)            | 8 (9.4)              | 0.005| 0.15 | 0.001| 0.11 |      |

DTC: Differentiated thyroid cancer, BTN: Benign thyroid nodule, SCH: Subclinical hyperthyroidism, P: Difference between SCH-DTC, euthyroid-DTC and euthyroid-BTN (Chi-square test), p* p** p***: Difference between SCH-DTC and euthyroid-BTN, P-value <0.05 was considered statistically significant.
4. Discussion

In our study, SCH-DTC group scored lower than euthyroid-BTN in most of the SF-36 QoL scores and lower than euthyroid-DTC in some of the SF-36 QoL scores. Among all malignancies, DTC has one of the highest remission rates and is associated with a high long-term survival rate [2]. The conventional treatment of DTC involves LT4 replacement and TSH suppression to minimize disease recurrence. However, the resulting subclinical hypothyroidism is associated with physical and psychological abnormalities that may adversely affect QoL [4,7]. In some cancer patients, being aware of the cancer diagnosis may also negatively affect their quality of life [22]. Therefore, diagnosing additional pathological conditions further impairing patients' quality of life may benefit survival. Vigario et al. reported that patients with...
SCH-DTC undergoing LT4 suppression treatment had a worse quality of life compared to those with euthyroid DTC [23]. Similarly, De Oliveira Chachamovitz et al. compared 38 patients with SCH-DTC and 54 patients with euthyroid DTC, and showed that patients with SCH-DTC had a lower quality of life than patients with euthyroid-DTC [7]. In these studies, fT4 levels in patients with SCH were significantly higher than the euthyroid group. In our study, since there were no difference between SCH-DTC and euthyroid-DTC groups in terms of fT4 levels, most of their quality of life scale scores were similar. Moreover, since fT4 level in SCH-DTC group was higher than euthyroid-BTN group, most of the quality of life scale scores were lower. It appears that quality of life is essentially affected by fT4 levels.

Thyroid dysfunction is known to cause significant mental symptoms and depression anxiety disorders are more common among patients with thyroid disorders [13]. Subclinical hyperthyroidism may cause affect disorders [24]. Panic attack and generalized anxiety are common disorders in thyroid dysfunction, particularly in overt hyperthyroidism [13,25–28]. However, data on whether SCH increases anxiety are limited and contradictory [29,30]. Thyroid hormones affect neuropsychiatric condition by increasing the activity of catecholamines. Studies have shown that thyroid hormones increases the number and activity of beta-catecholamine receptors [31,32]. Sait Gönen et al. reported significantly higher anxiety scoresand fT4 levels in patients with SCH compared to an euthyroid population [11]. Correlation analysis of our study showed a weak albeit significant correlation between TSH and fT4 levels and BAI scores. We found a significantly higher rate of moderate/severe anxiety in the SCH group (27.5%) than euthyroid-BTN. Here, the determining factor is the difference between fT4 levels. Subclinical hypothyroid-DTC and euthyroid-DTC groups, which had similar fT4 levels, were also similar in terms of anxiety severity. It was reported that even a minimal change in thyroid hormones can have behavioral effects [33]. Based on these data, it can be said that anxiety severity is affected by fT4 levels in SCH.

There is a small body of prospective data on the impact of SCH on depression [13]. Furthermore, studies with large patient series have yielded conflicting results [10,34]. In a 1219-patient study, Renate et al. concluded that patients with SCH had similar physical, cognitive functions and depression symptoms as euthyroid patients [34]. In a study of 1503 patients by Medici M et al., those with SCH had higher depressive symptom scores, and a prospective evaluation revealed that low TSH levels were associated with an increased incidence of depression [10]. The 3-year outcomes of another study showed that patients with SCH had higher depression scores than euthyroid ones [9]. Eustatia-Rutten et al. studied patients with DTC undergoing TSH suppression and showed that exogenously induced SCH was associated with higher depression scores than the euthyroid healthy control group [35]. Our study revealed similar rates of severe depression among SCH and control groups. TSH and BDI scores were not correlated. These differences may be due to the absence of the inclusion of multiple other factors affecting the results.

In conclusion; TSH suppression therapy administered for differentiated thyroid cancers are associated with significantly increased anxiety symptom scores but not depression scores. Most parameters of the QoL rating scale were negatively affected by TSH suppression. According to our findings, fT4 levels are correlated with anxiety in SCH-DTC, and it may have therefore caused disruption in the quality of life. It must be kept in mind that SCH induced by TSH suppression in patients with DTC can disrupt the patients’ psychological status and quality of life.

Acknowledgments/Disclaimers
The authors would like to thank the Department of Endocrinology and Metabolism and the Department of Biochemistry (Başkent University Faculty of Medicine) for the laboratory work. This study did not receive any financial funding and was performed as part of the employment duties of the authors. This study has been approved by Başkent University of Medical Sciences Ethics Committee and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The present study protocol was reviewed and approved by the Institutional Review Board of Başkent University College of Medicine (Approval no. KA14/314).

Conflict of interest
All of the authors declare that they have no competing interests. The authors also certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. Authors are those who have contributed to the conception and design of the article, the acquisition of data, or the analysis and interpretation of data, as well as the writing of the article or the revision of its content; and have read and approved the final version of the article before submission.
References

1. Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones (Athens, Greece) 2010; 9 (2): 103-108. doi: 10.14310/horm.2002.1260

2. Pacini F, Castagna MG. New insight in the follow-up strategies of differentiated thyroid cancer. Journal of Endocrinological Investigation 2012; 35 (6 Suppl): 36-39. 3. Donangelo I, Braunstein GD. Update on subclinical hyperthyroidism. American Family Physician 2011;83 (8): 933-938.

3. Collet TH, Gussekloo J, Bauer DC, Den Elzen WP, Cappola AR et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of Internal Medicine 2012;172 (10): 799-809. doi: 10.1001/archinternmed.2012.402

4. Vigario PS, Chachamovitz DS, Cordeiro MF, Teixeira PF, de Castro CL et al. Effects of physical activity on body composition and fatigue perception in patients on thyrotropin-suppressive therapy for differentiated thyroid carcinoma. Thyroid 2011; 21 (7): 695-700. doi: 10.1089/thy.2010.0052

5. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. The Journal of Endocrinology 2012; 213 (3): 209-221. doi: 10.1530/JEO-12-0059

6. De Oliveira Chachamovitz DS, Dos Santos Vigario P, Nogueira Cordeiro MF, de Castro CLN, Vaisman M et al. Quality of life, muscle strength, and fatigue perception in patients on suppressive therapy with levothyroxine for differentiated thyroid carcinoma. American Journal of Clinical Oncology 2013; 36 (4): 354-361. doi: 10.1097/COC.0b013e318248d864

7. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 2003; 25 (5): 349-356. doi: 10.1002/hed.10217

8. Blum MR, Wijsman LW, Virgini VS, Bauer DC, Den Elzen WP et al. Subclinical thyroid dysfunction and depressive symptoms among the elderly: a prospective cohort study. Neuroendocrinology 2016; 103 (3-4): 291-299. doi: 10.1159/000437387

9. Medici M, Direk N, Visser WE, Korevaar TJ, Hofman A et al. Thyroid function within the normal range and the risk of depression: a population-based cohort study. The Journal of Clinical Endocrinology and Metabolism 2014; 99 (4): 1213-1219. doi: 10.1210/jc.2013-3589

10. Sait Gönen M, Kisakol G, Savas Cilli A, Dikbas O, Gungor K et al. Assessment of anxiety in subclinical thyroid disorders. Endocrine Journal 2004; 51 (3): 311-315. doi: 10.1507/endocrj.51.311

11. Feldkamp J. Subclinical hyperthyroidism. Deutsche Medizinische Wochenschrift 2013; 138 (42): 2146-2150. doi: 10.1055/s-0033-1343278

12. Placidi GP, Boldrini M, Patronelli A, Fiore E, Chiovato L et al. Prevalence of psychiatric disorders in thyroid diseased patients. Neuropsychobiology 1998; 38 (4): 222-225. doi: 10.1159/000026545

13. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008; 29 (1): 76-131. doi: 10.1210/er.2006-0043

14. Singer S, Lincke T, Gamper E, Bhashkaran K, Schreiber S et al. Quality of life in patients with thyroid cancer compared with the general population. Thyroid 2012; 22 (2): 117-124. doi: 10.1089/thy.2011.0139

15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961; 4: 561-571. doi: 10.1001/archpsyc.1961.01710120031004

16. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988; 56 (6): 893-897. doi: 10.1037/0022-006x.56.6.893

17. Hissi N. Beck depresyon envanterinin üniversite öğrencileri için geçerlliği, güvenililiği (a reliability and validity study of Beck depression inventory in a university student sample). Journal of Psychology 1989; 7: 3-13.

18. Ulusoy M, Sahin NH, Erkmen H. The Beck anxiety inventory: psychometric properties. Journal of Cognitive Psychotherapy 1998; 12 (2): 163-172.

19. Ware JE. Scoring the SF-36. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA, USA: The Health Institute, New England Medical Center; 1993. pp.1-11.

20. Koçyiğit H, Aydemir O, Fışık G, Ölmž N, Memiş AK. Form-36 (KF-36)'nin Türkçe versiyonunu güvenililiği ve geçerlliği. İlaç ve Tedavi Dergisi 1999; 12 (2): 102-106.

21. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010; 20 (2): 173-179. doi: 10.1089/thy.2009.0187

22. Vigario PS, Chachamovitz DS, Teixeira Pde F, Rocque Mde L, Santos ML, Vaisman M. Exercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinoma. Arquivos Brasileiros de Endocrinologia and Metabologia 2014; 58 (3): 274-281. doi: 10.1590/0004-2730000002968

23. Wolkowitz OM, Rothschild AJ. Psychoneuroendocrinology: the scientific basis of clinical practice. Washington, DC, USA: American Psychiatric Publishing; 2008.

24. Denicoff KD, Joffe RT, Lakshmanan MC, Robbins J, Rubinow DR. Neuropsychiatric manifestations of altered thyroid state. The American Journal of Psychiatry 1990; 147 (1): 94-99. doi: 10.1176/ajp.147.1.94

25. Greer S, Ramsay I, Bagley C. Neurotic and thyrotoxic anxiety: clinical, psychological and physiological measurements. The British Journal of Psychiatry 1973; 122 (570): 549-554. doi: 10.1192/bjp.122.5.549
27. Simon NM, Blacker D, Korbly NB, Sharma SG, Worthington JJ et al. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. Journal of Affective Disorders 2002; 69 (1-3): 209-217. doi: 10.1016/s0165-0327(01)00378-0

28. Demet MM, Özmen B, Deveci A, Boyvada S, Adıgüzel H et al.. Depression and anxiety in hyperthyroidism. Archives of Medical Research 2002; 33 (6): 552-556. doi: 10.1016/s0188-4409(02)00410-1

29. Munjack DJ, Palmer R. Thyroid hormones in panic disorder, panic disorder with agoraphobia, and generalized anxiety disorder. The Journal of Clinical Psychiatry 1988; 49 (6): 229-231.

30. Engum A, Bjoro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function--a clinical fact or an artefact? Acta Psychiatrica Scandinavica 2002; 106 (1): 27-34. doi: 10.1034/j.1600-0447.2002.01250.x

31. Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. The Journal of Clinical Psychiatry 1993; 54 (2): 47-54.

32. Sulser F. Serotonin-norepinephrine receptor interactions in the brain: implications for the pharmacology and pathophysiology of affective disorders. The Journal of Clinical Psychiatry 1987; 48 Suppl:12-18.

33. Baldini IM, Vita A, Mauri MC, Amodei V, Carrisi M et al. Psychopathological and cognitive features in subclinical hypothyroidism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997; 21 (6): 925-935. doi:10.1016/s0278-5846(97)00089-4

34. De Jongh RT, Lips P, Van Schoor NM, Rijs KJ, Deeg DJ et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. European Journal of Endocrinology 2011; 165 (4): 545-554. doi:10.1530/EJE-11-0430

35. Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bax JJ et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clinical Endocrinology 2006; 64 (3): 284-291. doi:10.1111/j.1365-2265.2006.02458.x